

Monterrey, Mexico. July 15, 2013 – Alpek, S.A.B. de C.V. (BMV: ALPEK)

## Alpek reports U.S. \$122 million 2Q13 EBITDA, includes U.S. \$27 million expense provision related to the accelerated Cape Fear plant closure

### Selected Financial Information

(U.S. \$ Millions)

	2Q13	1Q13	2Q12	(% 2Q13 vs.)		YTD'13	YTD'12	Ch.%
				1Q13	2Q12			
<b>Total Volume (ktons)</b>	998	957	1,041	4	(4)	1,956	2,062	(5)
Polyester and Polyester Products	783	766	846	2	(7)	1,548	1,663	(7)
Plastics and Chemicals	216	192	195	13	11	407	400	2
<b>Consolidated Revenues</b>	1,811	1,825	1,913	(1)	(5)	3,637	3,809	(5)
Polyester and Polyester Products	1,380	1,422	1,496	(3)	(8)	2,802	2,992	(6)
Plastics and Chemicals	431	403	417	7	3	835	817	2
<b>Consolidated EBITDA<sup>(1)</sup></b>	122	160	201	(23)	(39)	282	396	(29)
Polyester and Polyester Products	72	119	144	(39)	(50)	191	283	(32)
Plastics and Chemicals	49	39	57	25	(15)	88	114	(23)
<b>Profit Attributable to Controlling Portion</b>	(71)	61	82	(217)	(187)	(10)	160	(107)
CAPEX and Acquisitions	60	66	27	(8)	120	126	39	220
Net Debt	644	747	645	(14)	(0)	644	645	(0)
Net Debt/LTM EBITDA <sup>(2)</sup>	1.1	1.1	0.8			1.1	0.8	
Interest Coverage <sup>(2)</sup>	5.9	6.5	7.8			5.9	7.8	

(1) Includes U.S.\$27 million Cape Fear expense provision. Proforma EBITDA is U.S. \$149 million in 2Q13 and U.S. \$309 million YTD'13.

(2) Times: Last 12 months.

### Operating & Financial Highlights (2Q13)

<b>ALPEK</b>	<ul style="list-style-type: none"> <li>Operating results remain in-line with original estimates; 2013 EBITDA guidance revised to U.S. \$623 million to reflect the U.S. \$27 million Cape Fear (CF) expense provision</li> <li>2Q13 net income impacted by U.S. \$114 million losses related to the accelerated closure of the CF site, including asset impairments, expense provision, and deferred tax</li> </ul>
<b>Polyester</b>	<ul style="list-style-type: none"> <li>Closure of the CF plant will allow Alpek to consolidate its polyester operations in more cost-efficient facilities</li> <li>U.S. \$30 million annual savings expected from CF's closure after September 2013</li> <li>Volume down 7% YoY reflecting CF transition and power outages in Mexico</li> </ul>
<b>Plastics &amp; Chemicals</b>	<ul style="list-style-type: none"> <li>11% volume growth driven by strong recovery in Polypropylene and EPS after 1Q13</li> <li>Plastics &amp; Chemicals EBITDA growth was offset by sustained weakness in CPL margins</li> <li>Caprolactam (CPL) margins remained below expectations; flat compared to 1Q13</li> </ul>

This release contains forward-looking information based on numerous variables and assumptions that are inherently uncertain. They involve judgments with respect to, among other things, future economic, competitive and financial market conditions and future business decisions, all of which are difficult or impossible to predict accurately. Accordingly, results could vary from those set forth in this release. The report presents unaudited financial information based on International Financial Reporting Standards (IFRS) in effect in Mexico beginning January 2012. Figures are stated in nominal Mexican pesos (\$) and in current U.S. Dollars (U.S. \$), as indicated. Where applicable, peso amounts were translated into U.S. Dollars using the average exchange rate of the months during which operations were recorded. Financial ratios are calculated in U.S. Dollars. Due to the rounding up of figures, small differences may occur when calculating percent changes from one period to the other.

### Message from the CEO

As we look to drive efficiencies in the business, we made the decision during the quarter to accelerate the closing of our Cape Fear site. Excluding the U.S. \$27 million Cape Fear expense provision, Alpek's 2Q13 EBITDA would have been U.S. \$149 million, in line with our original full-year guidance.

In accordance with IFRS, we recognized the full estimated amount associated with the Cape Fear closure during the second quarter. Our net income was negatively impacted by U.S. \$114 million, comprised of the aforementioned expense provision, plus U.S. \$157 million asset impairments, less U.S. \$70 million deferred tax.

Following the closure of the Cape Fear site, Alpek will consolidate its polyester operations and enhance its cost competitiveness by leveraging more efficient assets in its multi-site network. Cash savings in conversion, logistics and fixed costs are estimated to be approximately U.S. \$30 million per year, or U.S. \$300 million NPV, upon completion on September 2013. Furthermore, our combined production capabilities in the Americas, including recent debottleneck projects, will allow us to continue serving the market effectively and to grow with our customers.

As expected, polyester markets outside of North America continued to recover sequentially, following the gradual upward trend in Asian polyester margins that began after 4Q12. In addition, polypropylene (PP) and expandable polystyrene (EPS) volumes surged after the declines observed in 1Q13. Stable raw material (propylene) prices boosted polypropylene volume growth after the previous months' volatility. Moreover, increasing demand in the United States, Canada and South America contributed to the rise in EPS.

The ongoing recovery in polyester markets outside North America was offset by one-time events specific to the second quarter that negatively impacted the business. The first was the transition process to shut down the Cape Fear site and the second was multi-day power outages in Altamira and Cosoleacaque, Mexico. As a result, our Polyester business segment's volume decreased 7% year-on-year. However, we anticipate incremental volume in the coming months as a result of uninterrupted operations in Mexico, a more favorable polyester price environment and the seasonal demand increase during July and August.

Caprolactam (CPL) margins remained below expectations. Even though global CPL margins have been relatively stable throughout the first half of 2013, their current level is significantly lower year-on-year after the steep contraction observed in the second half of 2012. This year's weaker CPL margins caused the 15% decline in 2Q13 Plastics & Chemicals (P&C) EBITDA. However, during the second half of the year, we anticipate a reduced effect from CPL margin contraction as a result of continued margin stability and a lower CPL comparable base.

During the second quarter, we made significant progress in the implementation of our 2013 strategic investment priorities. As planned, our polyester operations will be consolidated through the announced closure of the Cape Fear site, the construction of our Cosoleacaque cogeneration facility is on-schedule with more than 80% progress, and the technical specification process of our Altamira cogeneration plant is underway. Most importantly, recent progress with potential partners is encouraging and we are focused on finalizing the definition stage of our MEG (Monoethyleneglycol) backward integration project.

## Results by Business Segment

### Polyester

(PTA, PET, Polyester fibers – 76% of Alpek’s Net Sales)

Alpek’s average polyester prices decreased 5% between the first and second quarter of 2013. The upward trend sustained by polyester prices since June 2012, shifted in March 2013 with a decline through May driven by falling oil and petrochemical feedstock prices (e.g. Paraxylene and MEG). The effect of price volatility on margins was mitigated by Alpek’s cost-plus pricing, but volume may be impacted temporarily. Typically, downward price trends have a short-term effect on demand as customers may defer some purchases by reducing their inventories.

Polyester volume decreased 7% year over year during 2Q13. In addition to a declining price environment in April and May, volume was negatively impacted by the initial transition process to shut down the Cape Fear site and several power outages that caused operations to be interrupted at the Altamira and Cosoleacaque sites. There is a temporary effect on volume and conversion costs as production at Cape Fear is ramped down and absorbed by other Alpek facilities. The Cape Fear site operated at utilization rates close to 50% in preparation for its closure. However, conversion costs are anticipated to decrease and volume is expected to stabilize once the consolidation process concludes in September 2013. Furthermore, polyester volume increased 2% when compared to 1Q13, in part, as the Columbia facility successfully ramped up production following the debottleneck project that was implemented in the beginning of the year.

Segment EBITDA was U.S. \$72 million in the second quarter, down 50% year over year, and 39% lower when compared to the first quarter. It is important to note that 2Q12 posted the highest EBITDA figure prior to the decline observed in polyester export margins during the second half of 2012. As expected, market conditions outside of North America extended their gradual improvement trend in the second quarter. However, the U.S. \$27 million Cape Fear expense provision, the operational ramp down at Cape Fear and power interruptions in Mexico impacted 2Q13 Polyester EBITDA. Excluding the Cape Fear expense provision, Polyester EBITDA amounted to U.S. \$99 million in the second quarter.

### Plastics and Chemicals (P&C)

(Polypropylene (PP), Expandable Polystyrene (EPS), Caprolactam (CPL), Other products – 24% of Alpek’s Net Sales)

Plastics & Chemicals volume increased 11% year over year during 2Q13 driven by strong demand in all products, including Caprolactam. Polypropylene volume surged 13% in the second quarter resulting from more stable raw material price conditions after the volatility observed in the first quarter. EPS volume also recovered in the second quarter from the decline posted in 1Q13. Incremental EPS exports to the United States, Canada and South America more than offset soft demand from the Mexican construction segment. Additionally, Caprolactam contributed to the P&C segment’s volume growth as a result of Alpek’s high CPL quality and recent efforts to increase the share of contract vs. spot sales.

2Q13 Plastics & Chemicals EBITDA decreased 15% year-on-year to U.S. \$49 million as global caprolactam margins have only improved slightly from historically low levels in 4Q12 after incremental capacity in China caused an abrupt contraction in CPL margins during the second half of 2012. However, P&C EBITDA posted a 25% rise when compared to 1Q13 driven by a strong sequential recovery in PP and EPS as well as stable CPL margins.

## Consolidated Financial Results

**Net Sales:** Net sales for the second quarter amounted to U.S. \$1,811 million, down 5% and 1% from 2Q12 and 1Q13, respectively. Polyester revenues decreased 8% year-on-year and 3% on a sequential basis as a result of lower volume and prices. In contrast, Plastic & Chemicals' net sales increased 3% on an annual basis and 7% on a quarterly basis driven by strong volume growth. Average dollar prices for both Polyester and Plastics & Chemicals decreased during the second quarter 2013 compared to 2Q12 and 1Q13, following lower oil and petrochemical feedstock prices.

**EBITDA:** 2Q13 EBITDA decreased 39% year over year to U.S. \$122 million. It is important to note that 2Q12 posted the highest consolidated EBITDA figure prior to the decline observed in caprolactam and polyester export margins during the second half of 2012. In addition, this quarter's EBITDA was negatively impacted by the U.S. \$27 million expense provision associated with the closure of the Cape Fear site to consolidate polyester production in more efficient plants. Excluding the Cape Fear expense provision, Alpek's consolidated EBITDA amounted to U.S. \$149 million in the second quarter and U.S. \$309 million year-to-date.

**Profit Attributable to Controlling Portion:** During 2Q13, the Company reported a Loss Attributable to the Controlling Portion of U.S. \$71 million, down 187% year-on-year as a result of the U.S. \$114 million net impact related to the announced closure of the Cape Fear site. Excluding the recognized losses associated with Cape Fear, the Profit Attributable to the Controlling Portion amounted to U.S. \$43 million for the quarter and U.S. \$104 million year-to-date.

**Capital Expenditures:** Capital expenditures reached U.S. \$60 million in 2Q13, increasing 120% year-on-year as a result of the ongoing investment in the construction of the Cosoleacaque cogeneration plant. Through the end of June, this project is more than 80% complete. Additionally, pursuant to a license agreement, Indelpro exercised its option to pay a lump sum royalty during the second quarter in connection to the use of the Spherizone® technology at its second polypropylene production line. Capital expenditures also include asset replacements and other smaller capital projects.

**Net Debt:** Consolidated Net Debt as of June 30, 2013 amounted to U.S. \$644 million, unchanged from the previous year but 14% below the balance as of March 31, 2013. The U.S. \$103 million sequential reduction in Net Debt resulted from prepayment of existing indebtedness as well as a larger cash balance. Financial ratios as of June 30, 2013 were: Net Debt to LTM EBITDA of 1.1 times and Interest coverage of 5.9 times, both of which were impacted by the U.S. \$27 million Cape Fear expense provision. Excluding the effect of Cape Fear losses, Net Debt to LTM EBITDA and Interest Coverage were 1.0x and 6.2x, respectively.

## Other Developments

**MSCI Index:** Alpek was removed from the MSCI Mexico Index as of May 31, 2013.

## Appendix A - Tables

**TABLE 1 | VOLUME (KTONS)**

	2Q13	1Q13	2Q12	(% ) 2Q13 vs.		YTD'13	YTD'12	Ch.%
				1Q13	2Q12			
Total Volume	998	957	1,041	4	(4)	1,956	2,062	(5)
Polyester	783	766	846	2	(7)	1,548	1,663	(7)
Plastics and Chemicals	216	192	195	13	11	407	400	2

**TABLE 2 | PRICE CHANGES (%)**

	(% ) 2Q13 vs.		YTD'13 vs.
	1Q13	2Q12	YTD'12
<b>Polyester</b>			
Avg. Ps. Prices	(7)	(7)	(4)
Avg. U.S. \$ Prices	(5)	(0)	1
<b>Plastics and Chemicals</b>			
Avg. Ps. Prices	(7)	(13)	(5)
Avg. U.S. \$ Prices	(5)	(6)	0
<b>Total</b>			
Avg. Ps. Prices	(7)	(8)	(4)
Avg. U.S. \$ Prices	(5)	(1)	1

**TABLE 3 | REVENUES**

	2Q13	1Q13	2Q12	(% ) 2Q13 vs.		YTD'13	YTD'12	Ch.%
				1Q13	2Q12			
<b>Total Revenues</b>								
Ps. Millions	22,616	23,284	25,729	(3)	(12)	45,900	50,558	(9)
U.S. \$ Millions	1,811	1,825	1,913	(1)	(5)	3,637	3,809	(5)
<b>Domestic Revenues</b>								
Ps. Millions	8,657	8,181	9,230	6	(6)	16,838	18,046	(7)
U.S. \$ Millions	693	641	687	8	1	1,335	1,361	(2)
<b>Foreign Revenues</b>								
Ps. Millions	13,959	15,103	16,499	(8)	(15)	29,062	32,512	(11)
U.S. \$ Millions	1,118	1,184	1,226	(6)	(9)	2,302	2,448	(6)
Foreign / Total (%)	62	65	64			63	64	

**TABLE 4 | OPERATING INCOME AND EBITDA**

	2Q13	1Q13	2Q12	(% 2Q13 vs.)		YTD'13	YTD'12	Ch.%
				1Q13	2Q12			
<b>Operating Income</b>								
Ps. Millions	(999)	1,523	2,166	(166)	(146)	524	4,202	(88)
U.S. \$ Millions	(75)	119	161	(163)	(147)	44	317	(86)
<b>EBITDA</b>								
Ps. Millions	1,525	2,035	2,707	(25)	(44)	3,560	5,257	(32)
U.S. \$ Millions	122	160	201	(23)	(39)	282	396	(29)

**TABLE 5 | COMPREHENSIVE FINANCING (EXPENSE) / INCOME (CF(E)/I) (U.S. \$ Millions)**

	2Q13	1Q13	2Q12	(% 2Q13 vs.)		YTD'13	YTD'12	Ch.%
				1Q13	2Q12			
Financial Expenses	(22)	(19)	(32)	(14)	31	(41)	(63)	34
Financial Income	3	3	7	(7)	(60)	6	12	(49)
Net Financial Expenses	(19)	(16)	(25)	(19)	23	(35)	(51)	30
Fx Gains (Losses)	(8)	7	2	213	(479)	(1)	15	(111)
Gas & Comm. Derivatives	0	0	(19)	0	(100)	0	(4)	(100)
CF(E)/ I	(27)	(9)	(42)	(192)	(36)	(36)	(40)	(9)

**TABLE 6 | NET INCOME (U.S \$ Millions)**

	2Q13	1Q13	2Q12	(% 2Q13 vs.)		YTD'13	YTD'12	Ch.%
				1Q13	2Q12			
Consolidated Net Income	(60)	77	91	(178)	(166)	17	187	(91)
Non-Controlling Portion	11	16	9	(30)	26	27	27	0
Controlling Portion	(71)	61	82	(217)	(187)	(10)	160	(107)
Earnings per Share (U.S. Dollars)	(0.03)	0.03	0.04	(217)	(184)	(0.00)	0.08	(106)
Avg. Outstanding Shares (Millions)	2,118	2,118	2,039			2,118	1,889	12

**TABLE 7 | CASH FLOW (U.S. \$ Millions)**

	2Q13	1Q13	2Q12	(% ) 2Q13 vs.		YTD'13	YTD'12	Ch.%
				1Q13	2Q12			
EBITDA	122	160	201	(23)	(39)	282	396	(29)
Net Working Capital & Others	86	(91)	(64)	194	235	(5)	(140)	96
Capital Expenditures & Acq.	(60)	(66)	(27)	8	(120)	(126)	(39)	(220)
Net Financial Expenses	(20)	(17)	(25)	(21)	19	(37)	(45)	19
Income tax	(23)	(19)	(50)	(22)	55	(41)	(82)	50
Dividends	0	(96)	0	(100)	0	(96)	(82)	(17)
Increase in Stockholder's Equity	0	0	749	0	(100)	0	749	(100)
Payment affiliated companies	0	0	(219)	0	100	0	(219)	100
Other Sources / Uses	(2)	(3)	(2)	17	(35)	(6)	5	(209)
Decrease (Increase) in Net Debt	103	(132)	563	(178)	82	(29)	542	105

**TABLE 8 | STATEMENT OF FINANCIAL POSITION & FINANCIAL RATIOS (U.S. \$ Millions)**

	2Q13	1Q13	2Q12	YTD'13	YTD'12
Assets	4,683	4,829	5,007	4,683	5,007
Liabilities	2,534	2,584	2,819	2,534	2,819
Stockholders' Equity	2,149	2,244	2,188	2,149	2,188
Net Debt	644	747	645	644	645
Net Debt/EBITDA*	1.1	1.1	0.8	1.1	0.8
Interest Coverage*	5.9	6.5	7.8	5.9	7.8

\* Times: last 12 months.

Polyester and Polyester Products

TABLE 9 | REVENUES

	2Q13	1Q13	2Q12	(% 2Q13 vs.)		YTD'13	YTD'12	Ch.%
				1Q13	2Q12			
<b>Total Revenues</b>								
Ps. Millions	17,231	18,140	20,110	(5)	(14)	35,371	39,703	(11)
U.S. \$ Millions	1,380	1,422	1,496	(3)	(8)	2,802	2,992	(6)
<b>Domestic Revenues</b>								
Ps. Millions	4,694	4,549	4,972	3	(6)	9,242	10,349	(11)
U.S. \$ Millions	376	357	371	5	1	733	782	(6)
<b>Foreign Revenues</b>								
Ps. Millions	12,537	13,591	15,138	(8)	(17)	26,129	29,354	(11)
U.S. \$ Millions	1,004	1,065	1,125	(6)	(11)	2,069	2,210	(6)
Foreign / Total (%)	73	75	75			74	74	

TABLE 10 | OPERATING INCOME AND EBITDA

	2Q13	1Q13	2Q12	(% 2Q13 vs.)		YTD'13	YTD'12	Ch.%
				1Q13	2Q12			
<b>Operating Income</b>								
Ps. Millions	(1,522)	1,099	1,509	(238)	(201)	(42)	2,913	(115)
U.S. \$ Millions	(117)	86	112	(236)	(204)	(31)	220	(114)
<b>EBITDA</b>								
Ps. Millions	894	1,513	1,933	(41)	(54)	2,407	3,746	(36)
U.S. \$ Millions	72	119	144	(39)	(50)	191	283	(32)



Plastics & Chemicals

TABLE 11 | REVENUES

	2Q13	1Q13	2Q12	(% 2Q13 vs.)		YTD'13	YTD'12	Ch.%
				1Q13	2Q12			
<b>Total Revenues</b>								
Ps. Millions	5,385	5,144	5,619	5	(4)	10,529	10,855	(3)
U.S. \$ Millions	431	403	417	7	3	835	817	2
<b>Domestic Revenues</b>								
Ps. Millions	3,963	3,632	4,259	9	(7)	7,595	7,697	(1)
U.S. \$ Millions	317	284	316	12	0	602	579	4
<b>Foreign Revenues</b>								
Ps. Millions	1,422	1,512	1,360	(6)	5	2,934	3,158	(7)
U.S. \$ Millions	114	119	101	(4)	13	233	238	(2)
Foreign / Total (%)	26	29	24			28	29	

TABLE 12 | OPERATING INCOME AND EBITDA

	2Q13	1Q13	2Q12	(% 2Q13 vs.)		YTD'13	YTD'12	Ch.%
				1Q13	2Q12			
<b>Operating Income</b>								
Ps. Millions	507	402	657	26	(23)	908	1,289	(30)
U.S. \$ Millions	40	32	49	28	(17)	72	97	(26)
<b>EBITDA</b>								
Ps. Millions	614	500	775	23	(21)	1,114	1,511	(26)
U.S. \$ Millions	49	39	57	25	(15)	88	114	(23)

## Appendix B – Financial Statements

ALPEK, S.A.B DE C.V. and Subsidiaries

### BALANCE SHEET

Information in millions of Mexican Pesos

	Jun-13	Mar-13	Jun-12	(% Jun 13 vs.)	
				Mar 13	Jun 12
<b>ASSETS</b>					
<b>CURRENT ASSETS:</b>					
Cash and cash equivalents	5,855	4,833	9,759	21	(40)
Trade accounts receivable	11,390	11,329	11,335	1	-
Other accounts and notes receivable	1,520	1,623	1,330	(6)	14
Inventories	11,707	11,567	12,808	1	(9)
Other current assets	1,720	1,652	1,828	4	(6)
<b>Total current assets</b>	<b>32,192</b>	<b>31,004</b>	<b>37,060</b>	<b>4</b>	<b>(13)</b>
Investment in shares	79	80	121	(2)	(35)
Property, plant and equipment, net	25,228	25,449	27,763	(1)	(9)
Goodwill and intangible assets, net	2,899	2,528	2,445	15	19
Other non-current assets	591	595	966	(1)	(39)
<b>Total assets</b>	<b>60,989</b>	<b>59,656</b>	<b>68,355</b>	<b>2</b>	<b>(11)</b>
<b>LIABILITIES AND STOCKHOLDER'S EQUITY</b>					
<b>CURRENT LIABILITIES:</b>					
Current portion of long-term debt	260	180	1,326	45	(80)
Bank loans and notes payable	511	432	1,067	18	(52)
Suppliers	10,177	9,679	10,534	5	(3)
Other current liabilities	3,618	2,646	3,461	37	5
<b>Total current liabilities</b>	<b>14,566</b>	<b>12,937</b>	<b>16,388</b>	<b>13</b>	<b>(11)</b>
<b>NON-CURRENT LIABILITIES:</b>					
Long-term debt	13,256	13,215	15,730	-	(16)
Deferred income taxes	3,765	4,497	4,905	(16)	(23)
Other liabilities	229	173	317	32	(28)
Employees' benefits	1,181	1,107	1,146	7	3
<b>Total liabilities</b>	<b>32,997</b>	<b>31,929</b>	<b>38,486</b>	<b>3</b>	<b>(14)</b>
<b>EQUITY:</b>					
Controlling portion:					
Capital stock	6,052	6,052	6,052	-	-
Share premium	9,071	9,071	9,071	-	-
Contributed capital	15,123	15,123	15,123	-	-
Earned surplus	9,395	9,443	11,208	(1)	(16)
Stockholders' equity controlling portion	24,518	24,566	26,331	-	(7)
Non-controlling portion	3,474	3,161	3,538	10	(2)
<b>Total equity</b>	<b>27,992</b>	<b>27,727</b>	<b>29,869</b>	<b>1</b>	<b>(6)</b>
<b>Total liabilities and equity</b>	<b>60,989</b>	<b>59,656</b>	<b>68,355</b>	<b>2</b>	<b>(11)</b>

## ALPEK, S.A.B DE C.V. and Subsidiaries

### STATEMENT OF INCOME

Information in millions of Mexican Pesos

	2Q13	1Q13	2Q12	YTD '13	YTD '12	2Q13 vs.(%)	
						1Q13	2Q12
Net sales	22,616	23,284	25,729	45,900	50,558	(3)	(12)
Domestic	8,657	8,181	9,230	16,838	18,046	6	(6)
Export	13,959	15,103	16,499	29,062	32,512	(8)	(15)
Cost of sales	(20,644)	(21,332)	(23,186)	(41,975)	(45,422)	3	11
Gross profit	1,972	1,952	2,543	3,925	5,136	1	(22)
Operating expenses and others	(2,971)	(429)	(377)	(3,401)	(934)	(593)	(687)
Operating income (loss)	(999)	1,523	2,166	524	4,202	(166)	(146)
Comprehensive financing expense, net	(336)	(117)	(562)	(453)	(525)	(188)	40
Equity in income (loss) of associates	(4)	(11)	(7)	(15)	(15)	67	49
Profit (loss) before income tax	(1,339)	1,395	1,597	56	3,662	(196)	(184)
Income tax	553	(415)	(371)	138	(1,184)	233	249
<b>Consolidated net income (loss)</b>	(786)	980	1,226	194	2,478	(180)	(164)
<b>Profit (loss) attributable to Controlling portion</b>	(928)	776	1,103	(153)	2,115	(220)	(184)
<b>Profit attributable to Non-controlling portion</b>	142	204	123	347	363	(30)	15